Biogen and the social contract
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
Dangling PD-1s emerge strong from three-day grilling
A US advisory panel has largely endorsed three anti-PD-(L)1 drugs, with voting apparently driven by the availability of alternatives.
Europe needs to be clearer about Covid-19 vaccines
Confusion over blood clot numbers with all four approved Covid-19 vaccines could cause more vaccine hesitancy.
Fresh antitrust push hits biopharma
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
